Search results
Results From The WOW.Com Content Network
Dengue virus (DENV) is the cause of dengue fever.It is a mosquito-borne, single positive-stranded RNA virus of the family Flaviviridae; genus Flavivirus. [1] [2] Four serotypes of the virus have been found, and a reported fifth has yet to be confirmed, [3] [4] [5] all of which can cause the full spectrum of disease. [1]
October 31, 2024 at 9:49 AM. Dengue fever cases rise to 6,800 in US amid 2 new infections in Los Angeles: CDC. The total number of dengue fever cases in the U.S. is now more than double the number ...
5,000 per year (2023) [7] Dengue fever is a mosquito-borne disease caused by dengue virus, prevalent in tropical and subtropical areas. It is frequently asymptomatic; if symptoms appear they typically begin 3 to 14 days after infection. These may include a high fever, headache, vomiting, muscle and joint pains, and a characteristic skin itching ...
An outbreak caused by serotype DENV-1 occurred in 2002 on Easter Island. Subsequent outbreaks occurred in 2006–2007 and 2008, 2009 and 2011 with decreasing magnitude over time. The male:female ratio in reported cases was approximately 1:1 and the average age at infection was 31.38 ± 18.37 in both sexes.
In October, California announced its first case of locally-transmitted dengue virus. ... the mortality rate of dengue is less than 1%—though that figure rises to 2-5% for severe dengue cases. If ...
In December 2018, Dengvaxia was approved in the European Union. [7]In May 2019, Dengvaxia was approved in the United States as the first vaccine approved for the prevention of dengue disease caused by all dengue virus serotypes (1, 2, 3 and 4) in people ages nine through 16 who have laboratory-confirmed previous dengue infection and who live in endemic areas.
The 2019–2020 dengue fever epidemic was an epidemic of the infectious disease dengue fever in several countries of Southeast Asia, including the Philippines, Malaysia, Vietnam, and Bangladesh, [ 1 ] Pakistan, [ 2 ] India, Thailand, Singapore, and Laos. [ 3 ] The spread of the disease was exacerbated by falling vaccination levels in certain ...
On Friday, Johnson & Johnson (NYSE:JNJ) announced discontinuing the Phase 2 field study evaluating the efficacy of investigational antiviral candidate mosnodenvir to prevent dengue virus in adults ...